BioSpace News Archive

Genentech, a member of the Roche Group, announced positive topline data from two Phase III multicenter studies evaluating Xolair® for the treatment of adults with chronic rhinosinusitis with nasal polyps who have not adequately responded to intranasal corticosteroids.

Targovax ASA announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a humanized mouse melanoma model has been accepted for publication in the Journal of Medical Virology.

Targovax ASA announces that a study showing abscopal effect of ONCOS-102 and Keytruda combination treatment in a humanized mouse melanoma model has been accepted for publication in the Journal of Medical Virology.

Medivir AB informs that new data from the phase I study of birinapant in combination with pembrolizumab was presented at an oral session on June 2nd at the American Society of Clinical Oncology annual meeting in Chicago, USA.

Incyte announced primary efficacy results from the Novartis-sponsored GEOMETRY mono-1 Phase 2 clinical trial of capmatinib, an investigational, selective MET inhibitor.

Chugai Pharmaceutical Co., Ltd. announced that the final progression-free survival data and the second interim analysis of overall survival from the Japanese phase III J-ALEX study for Alecensa® were presented on June 2 at the 2019 American Society of Clinical Oncology Annual Meeting, taking place from May 31 to June 4 in Chicago, IL, United States.

Thomas Langenickel, M.D. appointed to Chief Medical Officer as lead program ETH42 advances toward clinical trials

New Results Highlight the Importance of Objective Neurophysiological Measures and Clinically Meaningful Functional Outcomes

Echinococcus multilocularis is an emerging parasite in Canada.

Key linker element of Avacta’s novel TMAC™ drug conjugate to be tested in humans within 12 months